Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti …
Pirfenidone (PFD) is a non-peptide synthetic chemical that inhibits the production of
transforming growth factor-beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), platelet …
transforming growth factor-beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), platelet …
Role of pirfenidone in TGF-β pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical …
SH Hamidi, S Kadamboor Veethil, SH Hamidi - Pharmacological Reports, 2021 - Springer
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
pulmonary injury or multiple-organ injury by various pathological pathways. Transforming …
pulmonary injury or multiple-organ injury by various pathological pathways. Transforming …
Pirfenidone: A novel hypothetical treatment for COVID-19
S Seifirad - Medical hypotheses, 2020 - Elsevier
Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome
(ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A …
(ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A …
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung …
F Ferrara, G Granata, C Pelliccia, R La Porta… - European Journal of …, 2020 - Springer
Aim SARS-CoV-2 infection has been divided by scientific opinion into three phases: the first
as asymptomatic or slightly symptomatic and the second and the third with greater severity …
as asymptomatic or slightly symptomatic and the second and the third with greater severity …
[HTML][HTML] Role and new insights of pirfenidone in fibrotic diseases
DA Lopez-de la Mora, C Sanchez-Roque… - … journal of medical …, 2015 - ncbi.nlm.nih.gov
Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-
fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression …
fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression …
The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19
P Jiang, J Ye, M Jia, X Li, S Wei, N Li - Frontiers in pharmacology, 2022 - frontiersin.org
Background: Similar pathogenesis makes Corona Virus Disease 2019 (COVID-19)
associated with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and gouty arthritis …
associated with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and gouty arthritis …
Anti–coronavirus disease 2019 (COVID‐19) targets and mechanisms of puerarin
X Qin, C Huang, K Wu, Y Li, X Liang… - Journal of cellular and …, 2021 - Wiley Online Library
The present study aimed to uncover the pharmacological function and underlying
mechanism of puerarin as a potential treatment for COVID‐19, using an in silico …
mechanism of puerarin as a potential treatment for COVID‐19, using an in silico …
Vinpocetine is the forthcoming adjuvant agent in the management of COVID-19
Vinpocetine (VPN) is an alkaloid derivative of vincamine inhibits phosphodiesterase type 1
that increase cyclic guanosine monophosphate and cyclic adenosine monophosphate. VPN …
that increase cyclic guanosine monophosphate and cyclic adenosine monophosphate. VPN …
A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19
G Mostafa-Hedeab, HM Al-Kuraishy, AI Al-Gareeb… - …, 2022 - Springer
The existing pandemic viral infection caused by severe acute respiratory syndrome
coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS …
coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS …
Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail
SS Alkhayyat, HM Al-Kuraishy, AI Al-Gareeb… - Inflammation …, 2022 - Springer
Introduction Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha
(PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties …
(PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties …